FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations
Executive Summary
HHS blog post details activity of US FDA's Office of Prescription Drug Promotion during a year in which the office has only issued one enforcement letter, continuing a downward trend.
You may also be interested in...
Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
Office of Prescription Drug Promotion is focused on most egregious issues where human safety is at stake; CDER's Woodcock also says that First Amendment issues are affecting enforcement.
Xtampza ER Warnings Can't Be Hidden Behind Table And Chairs, US FDA Tells Collegium
OPDP's first enforcement letter of 2018 is notable because it comes much earlier than 2017's first, cites an opioid, and signals that the US FDA is monitoring medical meetings.
Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017
Last year's record low five letters came as FDA launched flurry of studies on DTC, professional ads; 'Bad Ad' complaints totaled more than 100.